Please complete the CAPTCHA to continue
@giiant.com
✓
4 phones found area 514
✓
LinkedIn matched
A concise factual answer block for searchers comparing this professional profile.
Maxime Ranger is listed as PhD MBA | Startup company creator | Life sciences at Neurenati, based in Blainville, Quebec, Canada. AeroLeads shows a work email signal at giiant.com, phone signal with area code 514, and a matched LinkedIn profile for Maxime Ranger.
Maxime Ranger previously worked as Chief Executive Officer at Neurenati and Cofounder - CEO at Numbio Therapeutics. Maxime Ranger holds Postdoc, Material Sciences & Drug Delivery from Stanford University.
This section adds company-level context without repeating Maxime Ranger's masked contact details.
AeroLeads found 2 current-domain work email signals for Maxime Ranger. Compare company email patterns before reaching out.
Serial entrepreneur who turned into venture capitalist in the life science space, specialized in the drug development: oncology, hepatology, gastroenterology and metabolic conditions, such as NASH, Prader-Willi Syndrome, type-2 diabetes and obesity. MBA, Ph.D. chemist with a scientific background in Material Sciences, more particularly in polymer chemistry. Two postdoc internships oriented to drug delivery, formulation development and nanolithography. Experience now extended to due diligence investigation, drug hunting and start-up financing. Co-authors of 30+ scientific publications in international peer-reviewed journals and co-inventors of 9 PCT-patented technologies.Specialties: CMC, formulation development, drug delivery, IND-enabling preclinical studies, clinical development strategies (Phase I & II). Pre-Seed, Seed, Series A/B Fundraising, Corporate affairs, licensing activities and IP strategy.
Listed skills include Drug Development, Entrepreneurship, Biotechnology, Gmp, and 11 others.
Company context helps verify the profile and gives searchers a useful next step.
A career timeline built from the work history available for this profile.
We have a therapeutic option ! Hirschsprung disease (HSCR) is a deadly birth defect affecting 1/5000 children. These children are missing innervation from the enteric nervous system (ENS), resulting in severe constipation and a high risk of bacterial translocation into blood causing premature death. Surgery to remove ENS-devoid bowel is generally.
Biotech startup focusing on tau-related neuropathies with first indication targeted is ophthalmology with glaucoma and macular degeneration.
Neolys Pharma develops novel orally-administered anticancer drugs for diverse drug-resistant cancers. Spin-out company from Laval University, with the support of Axelys.
OBaris develops new ways of drug delivery through the mouth mucosa.
Quebec, QC, CA
Developing novel anti-infectious drugs
Consultant for the following companies or VC funds: - Axelys (Montreal, Canada) - Biossil (Toronto, Canada) - HDAX (Toronto, Canada) - OligoMedic (Montreal, Canada) - Early-stage life science fund - undisclosed (Montreal, Canada)Privately-owned, consulting firm. Helping VC funds during fundraising. Accepting mandates to determine asset valuations, for M&A.
Montréal, QC, CA
Mandate renewed up to 2025. Chairman & internal jury member of thesis defences. Progress Report Committee member for Ph.D. students. Giving lectures from time to time.
Montreal, Quebec, CA
Advisor to the CEO, Christophe Mellon.EXIT - Worldwide exclusive license and partnership agreement signed with Palisade Bio. Cost sharing up to IND (with major contribution of the Partner). Projected IRR > 22% with a multiple > 2.8X for investors. Distribution will reach founders’ common stock.Shareholders: Founders, Employees, Genesys Capital, Fonds FTQ.
Montreal, Quebec, CA
CEO and chairman of the Board. Gastroenterology(GI)-focused company with a gut-restricted, colon-specific PDE4 inhibitor prodrug as lead program, to treat and manage inflammatory bowel diseases (IBD). The Company has a drug hunting club approach to identify and acquire GI focused assets in order to build a GI franchise in Precision Delivery.
Montréal, Québec, CA
Cette section est en français, car les pièces qui s’y déroulent sont dans la langue de Molière! Direction artistique: Claude Poissant. Directeur général: Stéphanie Laurin
Westmount, Quebec, CA
I remain ambassador of the event. First edition was April 2019 and the second one was organized October, 2021. The event remains an invitation-only to be organized in the Greater Montreal area. Second edition was virtual due to the covid pandemic. It remained a success. The third edition will be led by BioQuebec.
Laval, Québec, CA
Working with the CQIB Managing Director for partnership and alliance.
Québec, Québec, CA
Assisting the management during the fundraising, with Echelon-Stifel firms’ support. Phase 0/1 clinical stage company specializing in immunotherapy to treat allergies and fight cancers. First indication targeted is cat allergy vaccine, followed by peanut allergy vaccine. Veterinary applications with a signed animal health partner.
The intent is to raise a Seed Fund to support innovative research in life sciences within the Quebec ecosystem.
Montreal, Quebec, CA
EXIT - Inversago was acquired by Novo Nordisk for US$ 1.075B (August 2023).US$ 600M upfront payment plus total milestone payments to be paid, to reach US$ 1.075B Total investment CA$ 150M. Crystallized multiple 5X. Projected IRR > 37% with a multiple > 9X.Shareholders: Founders, Employees, NEA, Forbion Capital, Amgen Ventures, Genesys Capital, Fonds FTQ.
Montreal, Quebec, CA
Cofounder. Board Observer representing AmorChem, founding investor. Maintaining an active role on the Board, advising the CEO. Inversago focuses on the development of peripherally-restricted, orally-administered CB1 receptor inverse agonist in rare diseases, like Prader-Willi and lung fibrosis, and type-1 diabetes.
Montreal, Quebec, CA
Cofounder. Board member representing AmorChem, co-lead investor. Maintaining an active role as Board member, advising the CEO. Inversago focuses on the development of peripherally-restricted, orally-administered CB1 receptor inverse agonist in rare diseases, like Prader-Willi and lung fibrosis, and type-1 diabetes.
Montreal, Quebec, CA
Inversago Pharma is a start-up company focusing two families of novel dual-action, CB1 receptor antagonists / inverse agonists to be developed and used as anti-obesity drugs, including Prader-Willi Syndrome, with the ability to prevent and reverse liver fibrosis. Technology developed by Dr George Kunos at US NIH NIAAA.
Toronto, Ontario, CA
Venture Partner at Genesys Capital, a Canadian leading venture capital fund specialized in life sciences, investing equally in medical devices and drug therapeutics.
Westmount, Quebec, CA
EXIT - SemaThera signed a worldwide exclusive license with Roche (Febuary 2021). US$ 250M in total milestone payments to be paid. All development cost paid by Roche.Total investment < CA$ 5M. Crystallized multiple: 3.2X. Projected IRR > 38% with a multiple > 50X.Shareholders: Founders, employees, AmorChem and Senju Pharmaceutical.
Westmount, Quebec, CA
Chairman of the Board and close advisor to CEO. The Company is currently developing bispecific SEMA3A / VEGF inhibitors (traps) to prevent vascular leakage and damper the inflammation in diabetic macular edema (DME). This novel approach will shift the paradigm to a preventive and active therapy against DME.
Westmount, Quebec, CA
Being CEO until June 2018. SemaThera is a spin-off company from AmorChem Fund 1, which focuses on a novel target, semaphorin 3A (SEMA3A). The Company is currently developing bispecific SEMA3A / VEGF inhibitors (traps) to prevent vascular leakage and damper the inflammation in diabetic macular edema (DME). The technology targets the 30% DME patients who are.
Westmount, Quebec, CA
Advisor to CEO from Aug 2017 to Oct 2017. SemaThera is a spin-off company from AmorChem Fund 1, focusing on SEMA 3A inhibitors in the treatment of ocular diseases, especially diabetic macular edema. Technology developed by Dr Mike Sapieha at Hôpital Maisonneuve-Rosemont (HMR).
Westmount, Québec, CA
General Partner of AmorChem II Ventures, a leading early-stage life science Venture Fund which closed 45.7M$CAD for pre-seed, seed and Series A investments. The fund has the ability to identify disruptive and ground-breaking technologies from universities and turn them into newly-created companies with clear clinical development focus.
Westmount, Québec, CA
EIR starting first spin-out companies (Mperia Therapeutics, Corbin Therapeutics, SemaThera and MyX Therapeutics) from AmorChem 1 Ventures portfolio. Remain Chairman of the Board for MyX and SemaThera, and Board observer for Inversago.
The West Island Crisis Center’s mission is to meet the needs of adults experiencing a situational crisis, emotional distress, suicidal or otherwise. As well as to bring support to the loved ones of those in crisis. - La mission du Centre de crise de l’Ouest de l’Île est de répondre aux besoins des adultes en état de crise situationnelle, de détresse.
Montréal, Québec, CA
Co-investment made by AmorChem and adMare (CDRD/NeoMed) in an acid-sensing ion channels (ASIC) program, a novel class of pain management drugs, for neuropathy and cancer-inducing pain.
Montreal, Quebec, CA
Using mucoadhesive nanoparticle drug delivery platform
Montreal, Quebec, CA
MyX Therapeutics focuses on a mucoadhesive nanoparticle drug delivery platform, mainly for ophthalmic use, now diversifying its use to other applications.
Westmount, Quebec, CA
Developing inhibitors of USP15 against neuroinflammation
Westmount, Quebec, CA
Former CEO, now Board member advising the CEO. Corbin Therapeutics is a spin-off company from AmorChem Fund 1, developing a sophisticated in-vivo genome-wide screening platform in mice undergoing experimental neuro-inflammation, from the laboratory of Dr Philippe Gros, Faculty of Medicine, McGill University, leading to a novel anti-inflammatory target in.
Westmount, Quebec, CA
Corbin Therapeutics is a spin-off company from AmorChem Fund 1, developing a sophisticated in-vivo genome-wide screening platform in mice undergoing experimental neuro-inflammation, from the laboratory of Dr Philippe Gros, Faculty of Medicine, McGill University, leading to a novel anti-inflammatory target in the deubiquitinylation (DUB) family of enzymes..
Montreal, Quebec, CA
CD36 receptor technology targeting macrophage-driven inflammation
Montreal, Quebec, CA
CD36 receptor technology targeting macrophage-driven inflammation
Montreal, Quebec, CA
Mperia Therapeutics is spin-off company from AmorChem Fund 1, focusing on macrophage-driven inflammation via CD36 receptor immunometabolism. Lead candidates are CD36 receptor cyclic peptides, showing clear efficacy in dry form of age-related macular degeneration (dry AMD) and atherosclerosis models. Technology developed by Prof Huy Ong (Pharmacy) and.
Québec, Quebec, CA
At the time, it was Gestion Univalor and it became Axelys in 2021. Meeting professors in department and faculties at the University of Montreal. Assisting them with the invention disclosure statements and provisional patent filing. Establishing business relationship between the industry, venture capitalists, entrepreneurs and professors.
. Laurent Pharmaceuticals (Montreal, Canada) in Phase 2b/3. Inositec (Zurich, Switzerland) acquired by Vifor Pharma (2022). Versantis (Zurich, Switzerland) acquired by Genfit (2022)
Montreal, Quebec, CA
gIcare pharma is a clinical-stage, GI specialty company specialized in the development of novel colonic analgesic drugs for the visceral pain management of patients undergoing sedation-free, full colonoscopy. Such colonic analgesic drugs are non-centrally-acting opioid agonist with affinity to kappa and mu opioid receptor, capable of releasing a gaseous.
Montreal, Quebec, CA
Formerly Oncozyme Pharma, it became Verlyx. The Company has shifted its activities to liver disease alternatives. Give business and CMC support to Verlyx.
Montréal, Québec, CA
Board member (2011-2012). Board Observer (Mar 2010 - May 2011). Chairman of the Board (2006-2010). Non-profit / Charity Organization supporting financially Suicide Action Montreal. Main task based on fundraising. Raising annually 250K$+ through local business networking. Responsible for internal policies and corporate governance, in addition to.
Montecchio Maggiore, Vicenza, IT
Delmar Chemicals, which became a subsidary of F.I.S. s.p.a (Italy). Authorized representative BD. Delmar Chemicals is a CMO specialized the R-D synthesis and cGMP campaign, including pilot plant scale and commercial production. Synthesis mainly based on small molecules, polymers and excipients. Preparation of DMF (including IV type for new excipients)..
Saint-Hubert, Quebec, CA
Responsible for Global Business Development. KABS Pharmaceutical Services is a CMO offering a wide variety of services, including GLP analytical services, formulation development & cGMP manufacturing, in compliance with ICH and governmental authorities' requirements, including TPD's Health Canada, US FDA and EMEA.
MERGED WITH NUVECTOR. GInova Pharma Inc is a biotech company specialized in gastrointestinal drug development, including ground-breaking technologies were acquired, including a novel therapeutic approach to treat Celiac diseases, a chronic gluten-induced disorder.
MERGED WITH GINOVA PHARMA, due to common business activities. Nuvector Pharma Inc is a specialized biotech company focusing on innovative polymers, including polymer therapeutics and polymeric micelles in drug delivery. Polymeric Binders as Celiac disease treatment was in-licensed from University of Montreal, technology developed by Prof Jean-Christophe.
Initially Ecopia Biosciences and became Thallion (TSX:TLN) after merger with Caprion Pharmaceuticals Inc, acquired by Bellus Health. Responsible for the formulation development and CMC of 2 i.v. oncology drugs during preclinical & clinical phases. Supervising the outsourced cGMP manufacturing. Meeting with regulatory agencies, IND filings and clinical.
Bioxalis Medica, acquired by Procyon / Ambrilia Pharma. Development of CD-13 targeting liposome using NGR phospholipids and polymer-complex micronized celecoxib. Also includes business development, technology acquisition and due diligence processes.
Directing 7 talented scientists specialized in nano-drug delivery. Creation of Labopharm's Nanotechnology arm Focusing on a disruptive micelle technology platform for poorly water-soluble drugs. Labopharm acquired by Paladin (owned by Endo). Responsible for the development of novel taxane-loaded i.v. micelle formulations. In-vitro and in-vivo studies.
Quick answers generated from the profile data available on this page.
Maxime Ranger works for Neurenati.
Maxime Ranger is listed as PhD MBA | Startup company creator | Life sciences at Neurenati.
AeroLeads has found 2 work email signals at @giiant.com for Maxime Ranger at Neurenati.
AeroLeads has found 4 phone signal(s) with area code 514 for Maxime Ranger at Neurenati.
Maxime Ranger is based in Blainville, Quebec, Canada while working with Neurenati.
Maxime Ranger has worked for Neurenati, Numbio Therapeutics, Néolys Pharma, Obaris, and Matrix Innovation Inc..
You can use AeroLeads to view verified contact signals for Maxime Ranger at Neurenati, including work email, phone, and LinkedIn data when available.
Maxime Ranger holds Postdoc, Material Sciences & Drug Delivery from Stanford University.
Maxime Ranger is listed with skills including Drug Development, Entrepreneurship, Biotechnology, Gmp, Analytical Chemistry, Chemistry, Cmc, and Business Strategy.
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial Search contacts